Renal transplantation after myeloablative and non-myeloablative hematopoietic cell transplantation from the same donor.
Hematopoietic cell transplantation is a key treatment to prolong patient survival for many hematological disorders. Renal impairment is well recognized as a significant complication of hematopoietic cell transplantation, which can progress to end-stage renal disease. Herein, we report our experience of two patients who underwent renal transplantation from the same donor who provided cells for the preceding hematopoietic cell transplantation. One patient had undergone peripheral blood stem cell transplantation with a non-myeloablative conditioning regimen, whereas the other had received bone marrow transplantation with a myeloablative regimen. Chronic immunosuppressive therapy was not needed in either one to maintain the kidney graft function. Not only bone marrow transplantation with a myeloablative conditioning regimen, but also peripheral blood stem cell transplantation with a non-myeloablative regimen can confer immunological tolerance.
Tanaka
Toshiaki
T
Department of Urology, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo, Japan. zappa@pop12.odn.ne.jp
Ishida
Hideki
H
Shirakawa
Hiroki
H
Amano
Hiroyuki
H
Nishida
Hayato
H
Tanabe
Kazunari
K
D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000601:surgery; D016030:Kidney Transplantation; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D019172:Transplantation Conditioning
D007166:Immunosuppressive Agents